Organovo (NASDAQ: ONVO)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Organovo Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Organovo Company Info
News & Analysis
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
Will Organovo unlock the perceived value buried deep in its organ-printing technology by 2022?
Organovo is paying Amgen researchers for their ideas on studying 3D bioprinted tissues. It could be money well spent.
The 3D bioprinting company beat analyst revenue estimates in its fiscal first quarter -- but its losses worsened because of higher spending.
Organovo might be less risky than it's been in the past, but this stock still isn't for the faint of heart.
Shares dropped after the company reported uninspiring fourth-quarter results.
Could the beaten-down 3D bioprinting stock face even worse days ahead?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.